Flaws in the FDA’s New Priority Voucher Program

The FDA’s new Commissioner’s National Priority Voucher (CNPV) program is flawed, with broad and opaque eligibility criteria that risk politicizing drug approvals and undermining public trust. The program may have little impact on overall drug development timelines, while imposing burdens on agency staff and opening the door to conflicts of interest. The FDA should implement strong safeguards on the CNPV program to ensure transparency, fairness, and regulatory integrity.